This is a randomised trial in a NHS setting, comparing the clinical effectiveness and
cost-effectiveness of the selective serotonin reuptake inhibitor, escitalopram, and of the
tricyclic antidepressant, nortriptyline, to placebo, undertaken in a real-life setting in
addition to standard psychological care for the treatment of patients with depression in
Parkinson's disease. Participants will be randomly allocated 1:1:1 to receive escitalopram or
nortriptyline or placebo.
Phase:
Phase 3
Details
Lead Sponsor:
University College, London
Collaborators:
King's College London London North West Healthcare NHS Trust NHS Lothian University Hospital Plymouth NHS Trust